Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients

被引:0
|
作者
Zahed, L [1 ]
Mourad, FH [1 ]
Alameddine, R [1 ]
Aoun, S [1 ]
Koussa, S [1 ]
Taher, A [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
关键词
oral chelation; psychosocial status; thalassaemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
beta-Thalassemia requires life-long treatment, including regular blood transfusion and daily iron chelation by desferrioxamine, which places considerable burden on the social and psychological life of patients. It is expected that oral chelation therapy, which is easier to administer, would improve their psychosocial status. In this sutdy, interviews were conducted with a series of 44 patients recently placed on oral chelation therapy to evaluate their reactions to the new treatment. Eighty-six per cent of patients complied better with the oral chelation therapy. Fifty per cent of patients mentioned that relief from the desferrioxamine pump was the major improvement, while 47% felt psychologically better. Fifty per cent of patients noted improvements in their relationships, while 63% noted increased social activities. Evaluation of a larger sample of patients over a longer period of time is needed in order to confirm the favourable results obtained in this study.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [21] Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
    Mazza, P
    Amurri, B
    Lazzari, G
    Masi, C
    Palazzo, G
    Spartera, MA
    Giua, R
    Sebastio, AM
    Suma, V
    De Marco, S
    Semeraro, F
    Moscogiuri, R
    HAEMATOLOGICA, 1998, 83 (06) : 496 - 501
  • [22] Iron-chelation therapy with oral deferiprone - Toxicity or lack of efficacy?
    Kowdley, KV
    Kaplan, MM
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 468 - 469
  • [23] Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major
    Farmaki, Kalistheni
    Angelopoulos, Nicholas
    Anagnostopoulos, George
    Gotsis, Efstathios
    Rombopoulos, Grigorios
    Tolis, George
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (04) : 438 - 444
  • [24] Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy
    Sharma, Rajni
    Seth, Anju
    Chandra, Jagdish
    Gohain, Suraj
    Kapoor, Seema
    Singh, Pratiksha
    Pemde, Harish
    PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2016, 36 (01) : 22 - 27
  • [25] Iron and atherosclerosis: Inhibition by the iron chelator deferiprone (L1)
    Matthews, AJ
    Vercellotti, GM
    Menchaca, HJ
    Bloch, PHS
    Michalek, VN
    Marker, PH
    Murar, J
    Buchwald, H
    JOURNAL OF SURGICAL RESEARCH, 1997, 73 (01) : 35 - 40
  • [26] The International Study Group on Oral Iron Chelators: Results of long-term deferiprone (L1) therapy
    Hershko, C
    Hoffbrand, AV
    Olivieri, NF
    AlRefaie, FN
    Tondury, P
    Wonke, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 570 - 570
  • [27] The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels
    Fassos, FF
    Klein, J
    Fernandes, D
    Matsui, D
    Olivieri, NF
    Koren, G
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 (07) : 288 - 292
  • [28] PHARMACOKINETICS OF THE ORAL IRON CHELATOR DEFERIPRONE (L(1)) IN PATIENTS WITH IRON OVERLOAD
    ALREFAIE, FN
    SHEPPARD, LN
    NORTEY, P
    WONKE, B
    HOFFBRAND, AV
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) : 403 - 408
  • [29] Iron mobilisation from transferrin by deferiprone (L1)
    Kontoghiorghes, GJ
    Kolnagou, A
    Eracleous, E
    Evans, RW
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) : 157 - 157
  • [30] Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs
    Kontoghiorghes, George J.
    Kolnagou, Annita
    HAEMATOLOGICA, 2006, 91 : 34 - 35